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Abstract
Background: Nosocomial infections due to multi-drug resistant Acinetobacter baumannii are often
treated with colistin, but there are few data comparing its safety and efficacy with other
antimicrobials.
Methods: A retrospective cohort study of patients treated with colistin or tobramycin for A.
baumannii infections in intensive care units (ICUs) at Groote Schuur hospital. Colistin was used for
A. baumannii isolates which were resistant to all other available antimicrobials. In the tobramycin
group, 53% of the isolates were only susceptible to tobramycin and colistin. We assessed ICU
mortality, nephrotoxicity and time to the first negative culture.
Results: 32 patients, with similar admission APACHE scores and serum creatinine, were treated
with each antimicrobial. There were no significant differences between the colistin and tobramycin
groups in ICU mortality (p = 0.54), nephrotoxicity (p = 0.67), change in creatinine from baseline to
highest subsequent value (p = 0.11) and time to microbiological clearance (p = 0.75). The hazard
ratio for total in-hospital survival in patients treated with colistin compared to tobramycin was 0.43
(95% CI 0.19 to 0.99).
Conclusion: Our study suggests that colistin and tobramycin have similar risks of nephrotoxicity
and are equally efficacious. Colistin is an acceptable antibiotic for the treatment of A. baumanii
infections when the organism is resistant to other available antimicrobials.
Background
Colistin (polymyxin E) has been available since 1959.
Since the 1970's, other classes of antimicrobials, such as
the aminoglycosides or carbapenems were favoured for
gram-negative infections [1] because of concerns regard-
ing colistin's nephrotoxicity. However, the worldwide
emergence of multi-drug resistant nosocomial gram-nega-
tive pathogens over the last decade has resulted in the
increased use of colistin as last resort therapy [2,3].
Dosing recommendations for colistin vary considerably
[4], and, unlike aminoglycosides, therapeutic monitoring
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of colistin plasma concentrations is not readily available.
Nephrotoxicity has previously been shown to occur in
14.3 to 24% of patients treated with colistin in intensive
care units (ICUs) [5-7]. However, sepsis, hypotension and
the use of other nephrotoxic drugs may have contributed
to the impairment of renal function observed in these
studies.
In the intensive care units (ICUs) at Groote Schuur Hospi-
tal, multi-drug resistant Acinetobacter baumannii infections
have become common. Multi-drug resistant organisms
are defined as resistant to three or more antimicrobial
classes normally used for the treatment of infections [8].
The aminoglycoside tobramycin is the antimicrobial most
commonly prescribed at Groote Schuur for susceptible A.
baumannii infections but resistance to tobramycin occurs
commonly (41% of isolates in 2006). All A. baumannii
isolates at Groote Schuur Hospital remain susceptible to
colistin, which is prescribed when the organism is resist-
ant to all other available antimicrobials. Tobramycin or
colistin are used as monotherapy for Acinetobacter bau-
mannii infections at Groote Schuur Hospital. The aim of
our study was to compare the safety and effectiveness of
colistin versus tobramycin in ICU patients with A. bau-
mannii infections.
Methods
A retrospective chart review of patients in the ICUs of
Groote Schuur Hospital was conducted. Groote Schuur
Hospital is an 867-bed tertiary referral centre in Cape
Town, South Africa, with 56 ICU beds (respiratory, gen-
eral surgery and neurosurgery). All patients treated with
colistin for A. baumannii infections in Groote Schuur Hos-
pital ICUs between January 2003 and December 2005
were identified from pharmacy records.
Figure 1 shows the study profile. Pharmacy records iden-
tified 34 patients who had been treated with colistin and
143 with tobramycin for ICU-acquired A. baumannii infec-
tions. Two patients had received both colistin and
tobramycin during their ICU stay and were excluded from
the analysis. A total of 64 medical records were evaluated.
Every fourth patient who received tobramycin, in order of
date of admission to ICU, was included.
The patient's health status on admission as measured by
the Acute Physiology and Chronic Health Evaluation II
(APACHE) score, clinical course in ICU and other antimi-
crobials used were captured using a standardised data col-
lection form. Laboratory results were obtained from the
Groote Schuur National Health Laboratory Services elec-
tronic database.
Acinetobacter baumannii was tested for susceptibility to
piperacillin-tazobactam, colistin, ceftazidime, cefepime,
imipenem, meropenem, gentamicin, amikacin, tobramy-
cin and ofloxacin/ciprofloxacin and colistin. For all anti-
biotics except colistin, susceptibility testing was
performed using the Kirby-Bauer disc diffusion method
on Mueller Hinton agar (Oxoid). Minimum inhibitory
concentrations for colistin were determined by E-test (AB
Biodisk, Solna, Sweden) according to the manufacturer's
instructions. Interpretative criteria according to Clinical
Laboratory Standards Institute guidelines were used.
Study profile Figure 1
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The following were regarded as criteria to support the use
of antimicrobials for A baumannii: positive blood culture
for A. baumannii or culture of A. baumannii from other
sites associated with clinical signs of infection (a temper-
ature greater than 38°C, white cell count greater than
12×109/L, new chest x-ray infiltrates, the presence of puru-
lent sputum/tracheal aspirate or the necessity for ino-
tropic support) documented within 48 hours of
commencing the antimicrobial [9,10].
At Groote Schuur Hospital, colistin (Colimycine® Aventis,
Bellon, France) is administered at a dose of 2 million units
8 hourly in patients with normal renal function. The man-
ufacturers recommend 50 000 IU/kg/day in 2–3 divided
doses [11], which for a 70 kg adult amounts to 1.2 million
IU 8 hourly. Our practise is based on studies that have
used up to 3 million units 8 hourly [5,6], with toxicity
reported at these dosing levels not markedly increased
compared with the lower recommended doses.
Colistin dosage was adjusted for renal failure as follows:
creatinine clearance 50–90 ml/min 2 million units 12
hourly, creatinine clearance 10–50 ml/min 2 million
units 24 hourly and creatinine clearance less than 10 ml/
min 2 million units 36 hourly.
Tobramycin was given in doses of 5–6 mg/kg daily in
patients with normal renal function. In patients with a
creatinine clearance of less than 60 ml/minute, an initial
dose of 3–4 mg/kg was administered with further dosing
according to tobramycin plasma concentrations.
Efficacy outcomes assessed were microbiological clear-
ance and death while in ICU. Microbiological clearance
was defined as two or more consecutive negative cultures
for A. baumannii from all sites sampled, within 10 days of
initiation of the antimicrobial, with no subsequent posi-
tive cultures. The time to clearance was calculated as the
time interval between antimicrobial initiation and the
first negative culture.
The primary safety outcome assessed was the absolute
increase in creatinine from baseline (the day before the
antimicrobial was commenced) to the highest subsequent
recorded value within 10 days of initiation of the antimi-
crobial. Participants receiving haemodialysis at the time
antimicrobial therapy was first administered were
excluded from this analysis. The proportion of partici-
pants in each group who increased their serum creatinine
to greater than 50% above the upper limit of normal of
the local reference values (100 μmol/ml in females, 120
μmol/ml males) was compared. All other adverse effects
reported in the patient clinical records were recorded.
The study was approved by the University of Cape Town
Health Science Faculty Research Ethics Committee.
Statistical analysis
Data analysis was performed using Intercooled STATA™
version 8.2 (Statacorp, College Station, Texas). Continu-
ous variables were summarised using means and standard
deviations if normally distributed, and medians and
ranges if not normally distributed. 95% confidence inter-
vals (CIs) or interquartile ranges (IQRs) were calculated
for all summary statistics and parameter estimates.
Between-group comparisons of continuous data were per-
formed using a Student's t test if normally distributed, and
the Wilcoxon rank sum test if not normally distributed.
Proportions were compared using a two sample test of
proportions when the observed frequencies were ≥ 5 in
each group and the Fisher's exact test if the expected fre-
quencies were < 5. Kaplan-Meier curves were plotted for
time to microbiological clearance and time to death while
in ICU, and survival curves compared with a log-rank test.
Patients were censored when they were discharged from
ICU for the analysis of death and for death in the case of
microbiological clearance. For all statistical analyses, a p
value of less than 0.05 was regarded as sufficient evidence
to reject the null hypothesis.
Results
The baseline characteristics in the colistin and tobramycin
groups were similar with respect to age, APACHE score at
ICU admission and sites of isolation of A. baumannii
(Table 1). The median baseline serum creatinine was
higher in the colistin group (76 μmol/L) than in the
tobramycin group (56 μmol/L), but this difference was
not statistically significant (p = 0.08) Three patients in the
colistin group and 5 in the tobramycin group were on
haemodialyis at the time the antimicrobial was com-
menced and these proportions were not significantly dif-
ferent (Fishers exact test p = 0.7). Patients received a
median of 8 days of colistin (interquartile range (IQR) 5
to 13) and 7 days of tobramycin (IQR 6 to 10) (p = 0.72).
Either agent at our hospital is commenced after a review
of the case by a clinical microbiologist. In addition, all,
except one subject in the each group, had at least one fea-
ture to support the use of antimicrobial therapy for their
A. baumannii documented in their records. Twenty
patients (62.5%) in the colistin group and 22 (68.75%)
patients in the tobramycin group met the criteria for sepsis
(culture-positivity in conjunction with 2 or more compo-
nents of the Systemic Inflammatory Response Syndrome)
[10] at the time of initiation of the antimicrobial.
All the isolates in the colistin group were resistant to all
antimicrobials tested, except colistin. All the isolates in
the tobramycin group were susceptible to tobramycin. InBMC Infectious Diseases 2009, 9:26 http://www.biomedcentral.com/1471-2334/9/26
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17 of the tobramycin cases (53%), the organism was only
susceptible to tobramycin and colistin. Carbapenem
resistance was present in 24 (75%) of the tobramycin
group.
The median length of ICU stay after initiation of the anti-
microbial was 6 days (IQR 4 to 21) in the colistin group
and 9 days (IQR 4 to 21) in the tobramycin group (p =
0.06). Eleven colistin-treated patients (34.4%) and 7
tobramycin-treated patients (21.9%) died in ICU (p =
0.54). There was no significant difference in time to death
in ICU by Kaplan-Meier survival analysis (log rank p =
0.09) (figure 2). The hazard ratio for ICU survival in
patients treated with colistin compared with tobramycin
was 0.44 (95% CI 0.16 to 1.19).
The median length of total hospital stay after initiation of
the antimicrobial was 18 days (IQR 7 to 34) in the colistin
group and 27 days (IQR 12 to 56) in the tobramycin
group (p = 0.08) Sixteen patients treated with colistin
(50%) and 9 patients treated with tobramycin (28.1%)
died in hospital. The hazard ratio for total in-hospital sur-
vival in patients treated with colistin compared to
tobramycin was 0.43 (95% CI 0.19 to 0.99) (logrank p =
0.04) (see figure 3).
Bacteriological eradication was documented in 50% of
patients treated with colistin and 55% treated with
tobramycin (p = 0.79). The median time to clearance of A
baumannii was 3 days for colistin and 4 days for tobramy-
cin (p = 0.46). There was no significant difference in time
to microbiological clearance by Kaplan-Meier analysis
Table 1: Baseline patient characteristics
Colistin (n = 32) Tobramycin (n = 32) P value
Number of patients with chronic diseases at the time of admission (%) 9 (28) 12 (37.5) 0.65
Median duration of treatment (IQR) 8 (5 to 13) 7 (6 to 10) 0.72
Mean age in years (± SD) 43.5 (± 15.6) 45.6 (± 18.2) 0.69‡
Mean APACHE score at ICU admission (± SD) 14.4* (± 5.1) 14.8** (± 5.4) 0.77‡
Dialysis at baseline (%) 3 (9.4) 5 (15.6) 0.60†
Median baseline creatinine (IQR) umol/L 76 (53 to 128) 56 (45 to 91) 0.08
Site of A. baumannii infection:
Bloodstream infection 10 (31%) 10 (31%) 1.00
Sputum/tracheal aspirate 22 (72%) 28 (88%) 0.13†
Wound pus swab 6 (18.8%) 11 (34.4%) 0.75
Cerebrospinal fluid 1 (3.1%) 0 NA
Central venous catheter tip 10 (31%) 9 (28%) 0.44
Urine 5 (15.6%) 4 (12.5%) 1.00†
*data available for 25 participants **data available for 21 participants † Fisher's Exact Test ‡ Two sample t- test • Wilcoxon rank sum test  Two 
sample test of proportion
Kaplan- Meier ICU survival curves by antibiotic Figure 2
Kaplan- Meier ICU survival curves by antibiotic.
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Kaplan- Meier curves by antimicrobial for total in-hospital  survival Figure 3
Kaplan- Meier curves by antimicrobial for total in-
hospital survival.
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(figure 4) between the colistin and tobramycin groups
(log rank p = 0.75). The hazard ratio for microbiological
persistence in patients treated with colistin compared
with tobramycin was 0.90 (95% CI 0.46 to 1.76).
There was a modest increase in creatinine from baseline to
highest recorded within 10 days of antimicrobial com-
mencement in both groups, with a median increase of 28
μmol/mL (IQR 11 to 135) in those on colistin and 17
μmol/mL (IQR 6 to 22) in those on tobramycin (Wil-
coxon rank sum test p = 0.11). The geometric mean
change in creatinine in the colistin group was 42 μmol/L
(95% CI 24.4 to 74.9) and 19.6 μmol/L (12.1 to 31.6) in
the tobramycin group. Only one participant in the cohort
required initiation of haemodialysis after antimicrobial
therapy was commenced, a male patient with a baseline
serum creatinine of 118 μmol/mL 6 days after colistin ini-
tiation. The proportion of patients with normal renal
function at baseline who increased their creatinine con-
centrations to greater than 50% above the upper limit of
normal were similar in the two groups: 2 of 23 (8.7%) in
the tobramycin group and 4 of 21 (19%) in the colistin
group (Fishers exact test p = 0.67). No other adverse
effects were documented.
Ten patients in each group had bloodstream infections.
Colistin was used for a mean of 13 days (IQR 2 to 12.5)
and tobramycin 7.5 days (IQR 3.5 to 11.5) for blood-
stream infections (p = 0.25). Five patients in the tobramy-
cin group (50%) and 3 patients (30%) in the tobramycin
group with bloodstream infections died in ICU (p = 0.58).
Six patients with bloodstream infections in each group
(60%) were demonstrated to have achieved sustained
microbiological clearance.
Discussion
We found no significant differences in ICU survival, time
to microbiological clearance and elevations in serum cre-
atinine between the tobramycin and colistin groups.
These findings are encouraging, considering the uncer-
tainties regarding the optimal dose of colistin to maximise
efficacy while avoiding toxicity. Patients treated with col-
istin had higher in-hospital mortality; however we feel
that in-ICU mortality is the more important measure as
the ICU admission was the time period within which
patients were exposed to colistin or tobramycin.
Two uncontrolled studies reported an incidence of neph-
rotoxicity associated with colistin usage of 14% [5,6].
However, the absence of a comparator arm in these stud-
ies makes it difficult to distinguish the nephrotoxicity
induced by colistin from the effect of sepsis, hypotension
and other potentially nephrotoxic drugs used in ICU.
Several studies have compared colistin with the carbapen-
ems in ICU patients, and found that the mortality and
nephrotoxicity rates were not different in the colistin and
carbapenem groups [12-14]. However, in our intensive
care units, in common with many other centres, an
increasing proportion of A. baumannii isolates are resist-
ant to the carbapenems. Seventy five percent of isolates in
the tobramycin group in our study were carbapenem-
resistant. Because of increasing carbapemen resistance, A
baumannii  infections in our institution are likely to be
treated with either the aminoglycoside tobramycin, or col-
istin. To our knowledge there has been no study which
directly compared aminoglycoside monotherapy with
colistin. In one comparative study, 48% of patients in the
non-colistin group received an aminoglycoside (in com-
bination with a carbapenem, piperacillin-tazobactam or a
quinolone) [13]. These investigators found no significant
differences in mortality, the mean increase in creatinine or
rates of microbiological persistence at day 7 between col-
istin-exposed and non-exposed patients [15].
We compared colistin with tobramycin. In a study of once
daily administration of gentamicin and tobramycin in
ICU patients, 14% of participants were reported to have a
rise in creatinine of 45 μmol/mL or more [16]. Although
a modest increase in creatinine concentrations occurred in
both groups in our study, the magnitude was similar for
patients administered either colistin or tobramycin. The
cohort of ICU patients was heterogenous and at high risk
for the development of renal failure. Our results suggest
that colistin, when used in critically ill patients at rela-
Kaplan- Meier curves for microbiological clearance by antimi- crobial Figure 4
Kaplan- Meier curves for microbiological clearance 
by antimicrobial.
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tively high doses, is no more nephrotoxic than tobramy-
cin.
Our study has several limitations. The study population is
heterogenous, as we included all intensive care unit
patients with A. baumannii infections from any site. Clini-
cal patient information was gathered retrospectively,
resulting in some missing data and we were not able to
control for inter-observer variability. The sample size is
small, however as colistin is only prescribed when there
are no other available antimicrobials and sample sizes in
other studies have been similar. The primary outcome was
the change in creatinine concentration in those patients
who were not receiving dialysis. There was a high degree
of variability in the change in creatinine in the colistin
group and the 95% confidence intervals for the geometric
mean are wide. It is therefore possible that we failed to
demonstrate a difference between the colistin and
tobramycin groups because of our limited sample size. In
the ICU setting, sepsis, hypotension and the use of other
nephrotoxic drugs contribute to impairment of renal
function. We are not able to exclude the confounding
impact of these variables.
Conclusion
Our data suggests that colistin is not significantly different
to tobramycin in terms of efficacy or nephrotoxicity and
that it is an acceptable treatment of A. baumanii infections
when the organism is resistant to other available antimi-
crobials.
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